Copper Peptide Concentration: What Most Labels Don't Tell You
Published by AmpleLab Research
Copper peptides have become one of the most discussed actives in skincare and hair loss research. GHK-Cu in particular appears in hundreds of commercial serums, from budget formulations to premium skincare lines. The compound is real, the research behind it is solid, and consumer interest is well-founded.
What is less commonly discussed is how much copper peptide most of those products actually contain. The answer, readable directly from the ingredient label of almost any product, is typically far less than the research literature uses. This article explains how to read that information for yourself, why the gap exists, and what it means for a buyer.
This is not a claim that any particular product is ineffective. It is an argument for concentration transparency as a basic standard that the copper peptide market does not consistently meet.
Every cosmetic product sold in the UK and EU is required to list its ingredients in descending order of concentration by weight. This is the INCI list, the International Nomenclature of Cosmetic Ingredients, and it is a regulatory requirement, not a voluntary declaration. The ingredient listed first is present in the greatest quantity; the ingredient listed last is present in the least.
There is one exception: ingredients present at or below 1% may be listed in any order after those above 1%, and fragrances and flavours can be grouped. Otherwise, the order is informative and legally mandated.
This means that reading an INCI list gives you a reasonable map of what a product mostly consists of and, crucially, how far down the priority order any given active ingredient sits.
Reading the INCI List
In the majority of commercial copper peptide products, GHK-Cu (Copper Tripeptide-1) or AHK-Cu (Copper Tripeptide-3) appear toward the end of the INCI list, often after water, glycols, sodium hyaluronate, niacinamide, preservatives, and a range of other functional ingredients.
When an active ingredient appears after the preservative system, which in most formulations sits at around 0.5 to 1% of the total formula, it is almost certainly present at less than that. In practice, copper peptides in late-INCI-position products are often likely to be well below 1%.
This is not always easy to identify at a glance. Product names and marketing copy frequently lead with the copper peptide: "GHK-Cu Serum", "Copper Peptide Complex", "Tripeptide-1 Formula", without any indication of the actual concentration. The INCI list is buried in the small print, and without knowledge of what the order means, it reads as a list of ingredients rather than a ranked hierarchy.
The reasons are straightforward.
GHK-Cu is an expensive raw material relative to most cosmetic ingredients. AHK-Cu is more expensive still, produced in smaller quantities by fewer suppliers. Formulating at 1% means committing a significant portion of the product cost to a single active. Formulating at 0.05% allows a brand to include the ingredient on the label at a fraction of the cost, while marketing the product with the same headline claims.
UK and EU cosmetics regulations require INCI listing but do not require brands to state the percentage of each ingredient. A brand is legally permitted to list "Copper Tripeptide-1" on the label of a product that contains 0.01% of it. There is no mechanism to compel concentration disclosure, which means the burden falls entirely on the consumer to infer it from INCI position.
Cosmetic products do not require proof of efficacy before going to market. A brand does not need to demonstrate that its formulation produces a measurable result in users; it needs to demonstrate that the product is safe. This means the gap between a formulation that contains enough active ingredient to plausibly do something and one that contains a trace for marketing purposes is not regulated; it is a commercial choice.
Most buyers are not aware that INCI order communicates concentration, and fewer still know what INCI position implies about the actual percentage present. Marketing copy that leads with an ingredient name implies it is a primary active, even when it is present at a trace level.
The published research on copper peptides uses defined concentrations in experimental models. Many of these studies use concentrations that are difficult to compare directly with commercial topical formulations, as the relationship between an in vitro model concentration and what a topical product delivers to skin tissue is not straightforward.
This does not straightforwardly mean that a 1% topical formulation produces the same tissue concentrations as a 1% solution in a cell culture dish. Percutaneous penetration of peptides through the stratum corneum is an active area of research and genuine uncertainty remains about how much intact peptide-copper complex reaches the dermis from a standard aqueous topical application. A 2025 review on GHK-Cu skin permeation highlighted exactly this gap between formulation science and analytical capability.
What can be said with reasonable confidence is this: the concentration at the surface determines the concentration gradient driving passive penetration. A product at 0.05% has a substantially lower surface concentration than a product at 1%, which will produce a proportionally lower driving force for whatever passive penetration does occur. The relationship is not linear, but the direction is consistent.
Concentration in Context
Research literature: typically 0.1% to 1%+ in in vitro models
Most commercial products: 0.01% to 0.1%, estimated from INCI position
AmpleLab formulations: 1% stated explicitly (10mg/mL)
Concentration is not the only variable that matters. GHK-Cu is hydrophilic and does not readily cross the lipid-rich stratum corneum unaided. Research into delivery systems, including liposomal encapsulation and ionic liquid formulations, has shown improvements in percutaneous penetration compared to standard aqueous solutions. The 2025 Ogórek et al. review in Molecules noted that formulation may matter as much as the ingredient label.
Delivery does not eliminate the relevance of concentration, however. The concentration at the surface determines the gradient driving whatever passive penetration occurs. A product at a trace concentration has a proportionally lower starting point regardless of its carrier. Transparency about concentration remains a meaningful minimum standard.
When evaluating any copper peptide product, three things are worth checking.
The INCI name for GHK-Cu is Copper Tripeptide-1. For AHK-Cu it is Copper Tripeptide-3. Find either name in the ingredient list and note where it sits. If it appears after ingredients that are typically present at around the 1% level or below, such as sodium hyaluronate, niacinamide, or the preservative system, the copper peptide is likely below 1% as well. If it appears among the last several ingredients, it may be present at a trace level.
Some brands state the active concentration explicitly on the label or product page, which is the clearest indicator. If a brand is not forthcoming about concentration and deflects the question, that is informative. Brands that formulate at meaningful concentrations generally have an incentive to say so.
Glycol solvents, including propylene glycol, butylene glycol, and pentylene glycol, appear in many copper peptide formulations. For users with scalp or skin sensitivity, glycols are among the more common topical irritants. For users who incorporate microneedling into their routine, glycol-free formulations are also preferable given the increased skin penetration that microneedling provides. Neither consideration is specific to copper peptides, but both are relevant to choosing a carrier for a product applied regularly to sensitive or compromised skin.
AmpleLab states concentration explicitly on every product. GHK-Cu Face and Skin Serum is formulated at 1% (10mg/mL). AHK-Cu Hair and Scalp Serum is formulated at 1% (10mg/mL). Both use a glycol-free aqueous carrier. The INCI lists reflect this: Copper Tripeptide-1 and Copper Tripeptide-3 appear third in their respective ingredient lists, after water and glycerin, confirming their position as primary actives rather than trace additions.
This is not a claim that AmpleLab's formulations deliver copper peptides to the dermis more effectively than alternatives. It is a claim that the surface concentration is meaningful, that the carrier is clean, and that the information is available without hunting through marketing copy. Concentration transparency is the minimum standard for a brand asking an informed buyer to spend money on an active ingredient.
Does a lower concentration definitely mean a product is less effective?
Not definitively. Skin biology is complex, penetration dynamics are concentration-dependent and formulation-dependent, and the optimal topical dose for copper peptides in human skin has not been established by controlled clinical trials. What can be said is that formulating at a higher concentration is a more serious commitment to the active ingredient and provides a higher starting concentration gradient for whatever passive penetration occurs. The reverse, that trace levels are sufficient, is an assumption that has not been validated.
Why don't brands just state the concentration?
They are not required to. Concentration disclosure is voluntary in the UK and EU for cosmetic products. Brands that formulate at high concentrations have an incentive to disclose; brands that formulate at trace levels have an incentive not to. The INCI list is the only mandated transparency mechanism, and it requires some knowledge to interpret.
Is GHK-Cu at 0.1% doing nothing?
This article is not making that claim. Some in vitro research has observed GHK-Cu activity at nanomolar and micromolar concentrations, which correspond to very low percentage formulations. The question is not whether any amount does anything in any context; it is whether the amount in a given product is commensurate with the research literature and the price being charged for it. A product sold on the strength of GHK-Cu research and priced accordingly should at minimum be able to tell the buyer how much GHK-Cu it contains.
What is the INCI name for GHK-Cu?
The correct INCI name is Copper Tripeptide-1. Some products use alternative names including GHK-Cu, Tripeptide-1, or Glycyl-Histidyl-Lysine on their marketing material, but the INCI ingredient list should read Copper Tripeptide-1. AHK-Cu is listed as Copper Tripeptide-3, or alternatively as Alanine/Histidine/Lysine Polypeptide Copper HCl.
Does higher concentration cause any problems?
At 1%, GHK-Cu and AHK-Cu are within the range used in cosmetic formulations without known safety concerns at that level. The copper content of a 1% GHK-Cu serum is small in absolute terms; systemic absorption from a topical cosmetic is typically minimal. The published safety profile of copper peptides at cosmetic use concentrations does not identify concerns at 1%. As with any new topical, patch testing before first use is advisable.
This article is provided for educational purposes. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.